ANIK · Anika Therapeutics Inc
United States · RS rating 93 · As of 2026-10-14
| Price | 20.25 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 45 / 93 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 42 / 44 / 72 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +112.5% |
| Sales growth Q/Q | +10.1% |
| Distance from 52-week high | +8.1% |
| Market cap (USD) | $222.4M |